Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
Valérie Hox, Evelijn Lourijsen, Arnout Jordens, Kristian Aasbjerg, Ioana Agache, Isam Alobid, Claus Bachert, Koen Boussery, Paloma Campo, Wytske J. Fokkens, Peter W. Hellings, Claire Hopkins, Ludger Klimek, Mika J. Mäkelä, Ralph Mösges, Joaquim Mullol, Laura Pujols, Carmen Rondón, Michael Rudenko, Sanna Toppila‐Salmi, Glenis Scadding, Sophie Scheire, Peter Valentin Tomazic, Thibaut Van Zele, Martin Wagenmann, Job F. M. van Boven, Philippe Gevaert
Abstract
Because of the inflammatory mechanisms of most chronic upper airway diseases such as rhinitis and chronic rhinosinusitis, systemic steroids have been used for their treatment for decades. However, it has been very well documented that-potentially severe-side-effects can occur with the accumulation of systemic steroid courses over the years. A consensus document summarizing the benefits of systemic steroids for each upper airway disease type, as well as highlighting the potential harms of this treatment is currently lacking. Therefore, a panel of international experts in the field of Rhinology reviewed the available literature with the aim of providing recommendations for the use of systemic steroids in treating upper airway disease.